Golimumab for Adherence in Rheumatoid Arthritis

Sponsor
Janssen Inc.
Study ID
NCT03729349
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 85 Years
Healthy Volunteers
Not accepted

Interventions

  • Golimumab — BIOLOGICAL
    Participants will receive golimumab as a part of clinical practice.

Study Details

The purpose of this study is to determine if non-adherence to Rheumatoid Arthritis (RA) drugs in participants treated with biologic disease modifying anti-rheumatic drugs (DMARDs) is associated with a greater incidence of disease in clinical practice.

Key Dates

Start date
Jan 15, 2019
Status verified
Jul 2024
Primary completion
Jun 19, 2023
Completion
Jun 19, 2023

Study Design

Enrollment
222 participants (actual)

Arms

  • Arm: Participants with Diagnosis of Rheumatoid Arthritis
    Participants will not receive any intervention as a part of this study. All Rheumatoid Arthritis (RA) participants treated with golimumab in a clinical practice setting will be observed.

Primary Outcome Measure

Impact of Adherence on Flares as Assessed by Rheumatoid Arthritis Flare Questionnaire (RA-FQ) Score at 6 Month [ Time Frame: 6 Month ]

Related Studies